Core Laboratories (NYSE:CLB) Announces Quarterly Earnings Results

Core Laboratories (NYSE:CLB - Get Free Report) released its earnings results on Wednesday. The oil and gas company reported $0.19 earnings per share for the quarter, topping the consensus estimate of $0.18 by $0.01, Zacks reports. The business had revenue of $130.16 million for the quarter, compared to the consensus estimate of $129.19 million. Core Laboratories had a net margin of 5.73% and a return on equity of 14.15%. The firm's quarterly revenue was down .3% compared to the same quarter last year. During the same period last year, the firm posted $0.22 earnings per share. Core Laboratories updated its Q3 2025 guidance to 0.180-0.220 EPS.

Core Laboratories Stock Performance

Shares of Core Laboratories stock traded down $1.63 on Friday, reaching $11.73. The stock had a trading volume of 815,069 shares, compared to its average volume of 522,286. The business's 50-day moving average price is $11.83 and its two-hundred day moving average price is $13.87. The company has a debt-to-equity ratio of 0.47, a quick ratio of 1.64 and a current ratio of 2.27. Core Laboratories has a fifty-two week low of $10.14 and a fifty-two week high of $25.13. The stock has a market cap of $549.75 million, a P/E ratio of 18.91, a price-to-earnings-growth ratio of 3.61 and a beta of 1.41.

Core Laboratories Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Monday, August 25th. Stockholders of record on Monday, August 4th will be paid a $0.01 dividend. This represents a $0.04 dividend on an annualized basis and a dividend yield of 0.34%. The ex-dividend date of this dividend is Monday, August 4th. Core Laboratories's payout ratio is 6.45%.

Analyst Upgrades and Downgrades

Several research firms recently commented on CLB. Wall Street Zen upgraded shares of Core Laboratories from a "sell" rating to a "hold" rating in a report on Saturday. Citigroup reduced their target price on shares of Core Laboratories from $16.00 to $13.00 and set a "neutral" rating for the company in a research note on Tuesday, May 13th. Finally, Stifel Nicolaus reduced their target price on shares of Core Laboratories from $13.00 to $12.00 and set a "hold" rating for the company in a research note on Wednesday, July 16th.

Hedge Funds Weigh In On Core Laboratories

An institutional investor recently raised its position in Core Laboratories stock. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its stake in shares of Core Laboratories Inc. (NYSE:CLB - Free Report) by 4.4% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 27,893 shares of the oil and gas company's stock after acquiring an additional 1,170 shares during the quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. owned about 0.06% of Core Laboratories worth $418,000 at the end of the most recent reporting period. 97.81% of the stock is owned by hedge funds and other institutional investors.

Core Laboratories Company Profile

Core Laboratories Inc provides reservoir description and production enhancement services and products to the oil and gas industry in the United States, and internationally. It operates through Reservoir Description and Production Enhancement segments. The Reservoir Description segment includes the characterization of petroleum reservoir rock and reservoir fluid samples to enhance production and improve recovery of crude oil and gas from its clients' reservoirs.